Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keiichi Mitsuyama

Showing results (1-10 of 132) with videos related to

Pageof 14
Sort By:
Nihon Rinsho. Japanese Journal of Clinical Medicine|November 7, 2012
[Efficacy of probiotics in inflammatory bowel disease]Keiichi Mitsuyama
Nihon Rinsho. Japanese Journal of Clinical Medicine|May 11, 2005
[Probiotics and prebiotics for the treatment of inflammatory bowel disease]Keiichi Mitsuyama
Nihon Rinsho. Japanese Journal of Clinical Medicine|November 7, 2012
[Guidelines for treatment of Crohn's disease]Keiichi Mitsuyama
Cytotherapy|February 26, 2009
Therapeutic leukocytapheresis in inflammatory bowel disease: clinical efficacy and mechanisms of actionKeiichi Mitsuyama, Michio Sata
Expert Opinion on Therapeutic Targets|February 14, 2008
Gut microflora: a new target for therapeutic approaches in inflammatory bowel diseaseKeiichi Mitsuyama, Michio Sata
Current Pharmaceutical Design|June 13, 2009
Overview of the role of macrophage migration inhibitory factor (MIF) in inflammatory bowel diseaseJun Nishihira, Keiichi Mitsuyama
Current Pharmaceutical Design|June 13, 2009
Editorial: The impact of microbiota and cytokines on inflammatory bowel diseaseOsamu Kanauchi, Keiichi Mitsuyama
Current Pharmaceutical Design|June 13, 2009
The therapeutic impact of manipulating microbiota in inflammatory bowel diseaseOsamu Kanauchi, Keiichi Mitsuyama, Akira Andoh
Journal of Gastroenterology|February 8, 2003
Intestinal microflora as a therapeutic target in inflammatory bowel diseaseKeiichi Mitsuyama, Atsushi Toyonaga, Michio Sata
Journal of Gastroenterology|March 17, 2005
Immunoregulatory cytokines and intestinal inflammationKeiichi Mitsuyama, Atsushi Toyonaga, Michio Sata
Pageof 14

Showing results (1-10 of 132) with videos related to

Sort By:
Pageof 14
Nihon Rinsho. Japanese Journal of Clinical Medicine|November 7, 2012
[Efficacy of probiotics in inflammatory bowel disease]Keiichi Mitsuyama
Nihon Rinsho. Japanese Journal of Clinical Medicine|May 11, 2005
[Probiotics and prebiotics for the treatment of inflammatory bowel disease]Keiichi Mitsuyama
Nihon Rinsho. Japanese Journal of Clinical Medicine|November 7, 2012
[Guidelines for treatment of Crohn's disease]Keiichi Mitsuyama
Cytotherapy|February 26, 2009
Therapeutic leukocytapheresis in inflammatory bowel disease: clinical efficacy and mechanisms of actionKeiichi Mitsuyama, Michio Sata
Expert Opinion on Therapeutic Targets|February 14, 2008
Gut microflora: a new target for therapeutic approaches in inflammatory bowel diseaseKeiichi Mitsuyama, Michio Sata
Current Pharmaceutical Design|June 13, 2009
Overview of the role of macrophage migration inhibitory factor (MIF) in inflammatory bowel diseaseJun Nishihira, Keiichi Mitsuyama
Current Pharmaceutical Design|June 13, 2009
Editorial: The impact of microbiota and cytokines on inflammatory bowel diseaseOsamu Kanauchi, Keiichi Mitsuyama
Current Pharmaceutical Design|June 13, 2009
The therapeutic impact of manipulating microbiota in inflammatory bowel diseaseOsamu Kanauchi, Keiichi Mitsuyama, Akira Andoh
Journal of Gastroenterology|February 8, 2003
Intestinal microflora as a therapeutic target in inflammatory bowel diseaseKeiichi Mitsuyama, Atsushi Toyonaga, Michio Sata
Journal of Gastroenterology|March 17, 2005
Immunoregulatory cytokines and intestinal inflammationKeiichi Mitsuyama, Atsushi Toyonaga, Michio Sata
Pageof 14